DaVita Research Centers on Upstream CKD Management; Access & Equity during ASN's Kidney Week 2024

Core Insights - DaVita Clinical Research (DCR) is presenting five innovative research projects at the American Society of Nephrology's Kidney Week, focusing on improving racial equity in transplantation and clinical quality measures [1] - The research findings aim to enhance upstream chronic kidney disease (CKD) care management, prevent kidney failure, and promote health equity [1] Research Highlights - Nephrologist visits are associated with lower rates of hospitalization, mortality, and end-stage kidney disease (ESKD) transition in chronic kidney disease (CKD) patients [1] - Racial disparities in the transplant process have been identified among Hispanic patients on dialysis [1] - Heavy precipitation is linked to increased absenteeism in in-center dialysis treatment [1] - Early clinical indicators of ESKD transition or renal recovery have been studied in acute kidney injury (AKI) dialysis patients [1] - The study examines the relationship between systolic blood pressure thresholds and clinical outcomes in CKD stage 4/5 patients [1] Company Overview - DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally, serving approximately 265,100 patients at 3,124 outpatient dialysis centers as of June 30, 2024 [4] - DaVita has been a leader in clinical quality and innovation for over 20 years, working to reduce hospitalizations and improve mortality rates while promoting equitable care standards [4] - DCR assists pharmaceutical and medical device companies in designing and completing clinical trials through its renal research site network [3]